Acute exacerbation of COPD

Fanny W Ko, Ka Pang Chan, David S Hui, John R Goddard, Janet G Shaw, David W Reid, Ian A Yang, Fanny W Ko, Ka Pang Chan, David S Hui, John R Goddard, Janet G Shaw, David W Reid, Ian A Yang

Abstract

The literature of acute exacerbation of chronic obstructive pulmonary disease (COPD) is fast expanding. This review focuses on several aspects of acute exacerbation of COPD (AECOPD) including epidemiology, diagnosis and management. COPD poses a major health and economic burden in the Asia-Pacific region, as it does worldwide. Triggering factors of AECOPD include infectious (bacteria and viruses) and environmental (air pollution and meteorological effect) factors. Disruption in the dynamic balance between the 'pathogens' (viral and bacterial) and the normal bacterial communities that constitute the lung microbiome likely contributes to the risk of exacerbations. The diagnostic approach to AECOPD varies based on the clinical setting and severity of the exacerbation. After history and examination, a number of investigations may be useful, including oximetry, sputum culture, chest X-ray and blood tests for inflammatory markers. Arterial blood gases should be considered in severe exacerbations, to characterize respiratory failure. Depending on the severity, the acute management of AECOPD involves use of bronchodilators, steroids, antibiotics, oxygen and noninvasive ventilation. Hospitalization may be required, for severe exacerbations. Nonpharmacological interventions including disease-specific self-management, pulmonary rehabilitation, early medical follow-up, home visits by respiratory health workers, integrated programmes and telehealth-assisted hospital at home have been studied during hospitalization and shortly after discharge in patients who have had a recent AECOPD. Pharmacological approaches to reducing risk of future exacerbations include long-acting bronchodilators, inhaled steroids, mucolytics, vaccinations and long-term macrolides. Further studies are needed to assess the cost-effectiveness of these interventions in preventing COPD exacerbations.

Keywords: aetiology; chronic obstructive pulmonary disease; diagnosis; exacerbation; intervention.

© 2016 Asian Pacific Society of Respirology.

References

    1. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, et al. International variation in the prevalence of COPD (the BOLD study): a population‐based prevalence study. Lancet 2007; 370: 741‐50.
    1. Ko FW, Hui DS, Lai CK. Worldwide burden of COPD in high‐ and low‐income countries. Part III. Asia‐Pacific studies. Int. J. Tuberc. Lung Dis. 2008; 12: 713‐7.
    1. Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. Updated 2015. [Accessed 12 Jun 2015]. Available from URL:
    1. Lim S, Lam DC, Muttalif AR, Yunus F, Wongtim S, Lan le TT, Shetty V, Chu R, Zheng J, Perng DW, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia‐Pacific region: the EPIC Asia population‐based survey. Asia Pac. Fam. Med. 2015; 14: 4.
    1. Suzuki M, Makita H, Ito YM, et al. Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study. Eur. Respir. J. 2014; 43: 1289‐97.
    1. World Health Organisation . Chronic respiratory diseases, burden of chronic obstructive pulmonary disease. [Accessed 27 Jul 2015]. Available from URL: . 2015.
    1. Chan‐Yeung M, Lai CK, Chan KS, Cheung AH, Yao TJ, Ho AS, Ko FW, Yam LY, Wong PC, Tsang KW, et al. The burden of lung disease in Hong Kong: a report from the Hong Kong Thoracic Society. Respirology 2008; 13 Suppl 4: S133‐65.
    1. Hasegawa W, Yamauchi Y, Yasunaga H, Sunohara M, Jo T, Matsui H, Fushimi K, Takami K, Nagase T. Factors affecting mortality following emergency admission for chronic obstructive pulmonary disease. BMC Pulm Med. 2014; 14: 151.
    1. Chang CL, Sullivan GD, Karalus NC, Mills GD, McLachlan JD, Hancox RJ. Predicting early mortality in acute exacerbation of chronic obstructive pulmonary disease using the CURB65 score. Respirology. 2011; 16: 146–51.
    1. Lou P, Zhu Y, Chen P, Zhang P, Yu J, Zhang N, Chen N, Zhang L, Wu H, Zhao J. Vulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: a cross‐sectional study. BMC Public Health. 2012; 12: 287.
    1. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006; 61: 250‐8.
    1. Choi KJ, Cha SI, Shin KM, Lee J, Hwangbo Y, Yoo SS, Lee Sy, Kim CH, Park JY, Jung TH. Prevalence and predictors of pulmonary embolism in Korean patients with exacerbation of chronic obstructive pulmonary disease. Respiration 2013; 85: 203‐9.
    1. Wark PA, Tooze M, Powell H, Parsons K. Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission. Respirology 2013; 18: 996‐1002.
    1. Mohan A, Chandra S, Agarwal D, Guleria R, Broor S, Gaur B, Pandey RM. Prevalence of viral infection detected by PCR and RT‐PCR in patients with acute exacerbation of COPD: a systematic review. Respirology 2010; 15: 536‐42.
    1. Ko FW, Ip M, Chan PK, Fok JP, Chan MC, Ngai JC, Chan DP, Hui DS. A 1‐year prospective study of the infectious etiology in patients hospitalized with acute exacerbations of COPD. Chest 2007; 131: 44‐52.
    1. Ko FW, Ip M, Chan PK, Chan MC, To KW, Ng SS, Chau SS, Tang JW, Hui DS. Viral etiology of acute exacerbations of COPD in Hong Kong. Chest 2007; 132: 900‐8.
    1. Cameron RJ, de Wit D, Welsh TN, Ferguson J, Grissell TV, Rye PJ. Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. Intensive Care Med. 2006; 32: 1022‐9.
    1. Ye F, He LX, Cai BQ, Wen FQ, Chen BY, Hadiarto M, Chen RC, Yuan JP, Sun HL. Spectrum and antimicrobial resistance of common pathogenic bacteria isolated from patients with acute exacerbation of chronic obstructive pulmonary disease in mainland of China. Chin Med J (Engl) 2013; 126: 2207‐14.
    1. Lin SH, Kuo PH, Hsueh PR, Yang PC, Kuo SH. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa . Respirology 2007; 12: 81‐7.
    1. Hui DS, Ip M, Ling T, Chang SC, Liao CH, Yoo CG, Kim DK, Yoon HI, Udompanich V, Mogmeud S, et al. A multicentre surveillance study on the characteristics, bacterial aetiologies and in vitro antibiotic susceptibilities in patients with acute exacerbations of chronic bronchitis. Respirology 2011; 16: 532‐9.
    1. Lee IM, Tsai SS, Chang CC, Ho CK, Yang CY. Air pollution and hospital admissions for chronic obstructive pulmonary disease in a tropical city: Kaohsiung, Taiwan. Inhal. Toxicol. 2007; 19: 393‐8.
    1. Ko FW, Tam W, Wong TW, Chan DP, Tung AH, Lai CK, Hui DS. Temporal relationship between air pollutants and hospital admissions for chronic obstructive pulmonary disease in Hong Kong. Thorax 2007; 62: 780‐5.
    1. Zhang Z, Wang J, Chen L, Chen X, Sun G, Zhong N, Kan H, Lu W. Impact of haze and air pollution‐related hazards on hospital admissions in Guangzhou, China. Environ. Sci. Pollut. Res. Int. 2014; 21: 4236‐44.
    1. Tian L, Ho KF, Wang T, Qiu H, Pun VC, Chan CS, Louie PK, Yu IT. Ambient carbon monoxide and the risk of hospitalization due to chronic obstructive pulmonary disease. Am J Epidemiol. 2014; 180: 1159–67.
    1. Qiu H, Yu IT, Tian L, Wang X, Tse LA, Tam W, Wong TW. Effects of coarse particulate matter on emergency hospital admissions for respiratory diseases: a time‐series analysis in Hong Kong. Environ Health Perspect. 2012; 120: 572–6.
    1. Li MH, Fan LC, Mao B, Yang JW, Choi AM, Cao WJ, Xu JF. Short Term Exposure to Ambient Fine Particulate Matter (PM2.5) Increases Hospitalizations and Mortality of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta‐Analysis. Chest 2015; DOI:10.1378/chest.15-0513 [Epub ahead of print]
    1. Kan H, Chen B. Air pollution and daily mortality in Shanghai: a time‐series study. Arch Environ Health. 2003; 58: 360–7.
    1. Meng X, Wang C, Cao D, Wong C, Han H. Short‐term effect of ambient air pollution on COPD mortality in four Chinese cities. Atmospheric Environment 2013; 77: 149–54.
    1. Hedley AJ, Wong CM, Thach TQ, Ma S, Lam TH, Anderson HR. Cardiorespiratory and all‐cause mortality after restrictions on sulphur content of fuel in Hong Kong: an intervention study. Lancet. 2002; 360: 1646–52.
    1. Tian L, Qiu H, Pun VC, Lin H, Ge E, Chan JC, Louie PK, Ho KF, Yu IT. Ambient carbon monoxide associated with reduced risk of hospital admissions for respiratory tract infections. Am J Respir Crit Care Med. 2013; 188: 1240–5.
    1. Bathoorn E, Slebos DJ, Postma DS, Koeter GH, van Oosterhout AJ, van der Toorn M, Boezen HM, Kerstjens HA. Anti‐inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study. The European respiratory journal. 2007; 30: 1131–7.
    1. Eisner MD, Iribarren C, Yelin EH, Sidney S, Katz PP, Sanchez G, Blanc PD. The impact of SHS exposure on health status and exacerbations among patients with COPD. Int J Chron Obstruct Pulmon Dis. 2009; 4: 169–76.
    1. Ko FW, Hui DS. Air pollution and chronic obstructive pulmonary disease. Respirology. 2012; 17: 395–401.
    1. Tseng CM, Chen YT, Ou SM, Hsiao YH, Li SY, Wang SJ, Yang AC, Chen TJ, Perng DW. The effect of cold temperature on increased exacerbation of chronic obstructive pulmonary disease: a nationwide study. PLoS One. 2013; 8: e57066.
    1. Huang F, Zhao A, Chen RJ, Kan HD, Kuang XY. Ambient temperature and outpatient visits for acute exacerbation of chronic bronchitis in Shanghai: a time series analysis. Biomed Environ Sci. 2015; 28: 76–9.
    1. Qiu H, Yu IT, Wang X, Tian L, Tse LA, Wong TW. Season and humidity dependence of the effects of air pollution on COPD hospitalizations in Hong Kong. Atmospheric Environment. 2013; 76: 74–80.
    1. Rea H, McAuley S, Jayaram L, Garrett J, Hockey H, Storey L, O'Donnell G, Haru L, Payton M, O'Donnell K. The clinical utility of long‐term humidification therapy in chronic airway disease. Respir Med. 2010; 104: 525–33.
    1. Gunen H, Gulbas G, In E, Yetkin O, Hacievliyagil SS. Venous thromboemboli and exacerbations of COPD. The European respiratory journal. 2010; 35: 1243–8.
    1. Dutt TS, Udwadia ZF. Prevalence of venous thromboembolism in acute exacerbations of chronic obstructive pulmonary disease: an Indian perspective. Indian J Chest Dis Allied Sci. 2011; 53: 207–10.
    1. Duan SC, Yang YH, Li XY, Liang XN, Guo RJ, Xie WM, Kuang TG, Dai HP, Wang C. Prevalence of deep venous thrombosis in patients with acute exacerbation of chronic obstructive pulmonary disease. Chin Med J (Engl). 2010; 123: 1510–4.
    1. Erelel M, Cuhadaroglu C, Ece T, Arseven O. The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med. 2002; 96: 515–8.
    1. Verduri A, Luppi F, D'Amico R, Balduzzi S, Vicini R, Liverani A, Ruggieri V, Plebani M, Barbaro MPF, Spanevello A et al. et al. Antibiotic Treatment of Severe Exacerbations of Chronic Obstructive Pulmonary Disease with Procalcitonin: A Randomized Noninferiority Trial. PLoS ONE. 2015; 10: e0118241.
    1. Sethi S. Chronic Obstructive Pulmonary Disease and Infection. Disruption of the Microbiome? Annals of the American Thoracic Society 2014; 11: S43–S7.
    1. Shaw JG, Vaughan A, Dent AG, O'Hare PE, Goh F, Bowman RV, Fong KM, Yang IA. Biomarkers of progression of chronic obstructive pulmonary disease (COPD). Journal of Thoracic Disease. 2014; 6: 1532–47.
    1. Molyneaux PL, Mallia P, Cox MJ, Footitt J, Willis‐Owen SA, Homola D, Trujillo‐Torralbo MB, Elkin S, Kon OM, Cookson WO et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 188: 1224–31.
    1. Huang YJ, Kim E, Cox MJ, Brodie EL, Brown R, Wiener‐Kronish JP, Lynch SV. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS. 2010; 14: 9–59.
    1. Millares L, Ferrari R, Gallego M, Garcia‐Nuñez M, Pérez‐Brocal V, Espasa M, Pomares X, Monton C, Moya A, Monsó E. Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2014; 33: 1–11.
    1. Huang YJ, Sethi S, Murphy T, Nariya S, Boushey HA, Lynch SV. Airway Microbiome Dynamics in Exacerbations of Chronic Obstructive Pulmonary Disease. Journal of Clinical Microbiology. 2014; 52: 2813–23.
    1. Su J, Liu H‐y, Tan X‐l, Ji Y, Jiang Y‐x, Prabhakar M, Rong Z‐h, Zhou H‐w, Zhang G‐x. Sputum Bacterial and Fungal Dynamics during Exacerbations of Severe COPD. PLoS ONE. 2015; 10: e0130736.
    1. Smith DJ, Badrick AC, Zakrzewski M, Krause L, Bell SC, Anderson GJ, Reid DW. Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. Eur Respir J. 2014; 44: 922–30.
    1. Simpson JL, Powell H, Baines KJ, Milne D, Coxson HO, Hansbro PM, Gibson PG. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS One. 2014; 9: e105609.
    1. Brill SE, Law M, El‐Emir E, Allinson JP, James P, Maddox V, Donaldson GC, McHugh TD, Cookson WO, Moffatt MF et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax 2015; 70: 930–8.
    1. Turner MO, Patel A, Ginsburg S, FitzGerald JM. Bronchodilator delivery in acute airflow obstruction. A meta‐analysis. Arch Intern Med. 1997; 157: 1736–44.
    1. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G. Device selection and outcomes of aerosol therapy: Evidence‐based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005; 127: 335–71.
    1. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta‐agonist treatment of acute asthma. Cochrane Database Syst Rev. 2013; 9: CD000052.
    1. Mazhar SH, Ismail NE, Newton DA, Chrystyn H. Relative lung deposition of salbutamol following inhalation from a spacer and a Sidestream jet nebulizer following an acute exacerbation. British journal of clinical pharmacology. 2008; 65: 334–7.
    1. Simonds AK, Hanak A, Chatwin M, Morrell M, Hall A, Parker KH, Siggers JH, Dickinson RJ. Evaluation of droplet dispersion during non‐invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health technology assessment (Winchester, England) 2010; 14(131): 72.
    1. Holland A, Smith F, Penny K, McCrossan G, Veitch L, Nicholson C. Metered dose inhalers versus nebulizers for aerosol bronchodilator delivery for adult patients receiving mechanical ventilation in critical care units. The Cochrane database of systematic reviews 2013; 6: Cd008863.
    1. Woods JA, Wheeler JS, Finch CK, Pinner NA. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014; 9: 421–30.
    1. Japanese Respiratory Society . Guidelines for the Diagnosis and Treatment of COPD. 3rd edition. 2010. [Accessed 20 Nov 2015]. Available from URL:
    1. Thoracic Society of Australia and New Zealand . The COPD‐X plan. [Accessed 26 Oct 2015]. Available from URL:
    1. Malaysian Thoracic Society . Management of chronic obstructive pulmonary disease. 2nd edition. 2009. [Accessed 20 Nov 2015]. Available from URL:
    1. Philippine College of Chest Physician . Clinical practice guidelines in the diagnosis and management of chronic obstructive pulmonary disease (COPD) in the Philippines, 2nd update. 2009. [Accessed 16 Nov 2015]. Available from URL:
    1. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S et al. Short‐term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. Jama. 2013; 309: 2223–31.
    1. Walters JA, Tan DJ, White CJ, Wood‐Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014; 12: CD006897.
    1. Ceviker Y, Sayiner A. Comparison of two systemic steroid regimens for the treatment of COPD exacerbations. Pulm Pharmacol Ther. 2014; 27: 179–83.
    1. de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double‐blind study. Chest. 2007; 132: 1741–7.
    1. Wang PH, Cheng SL, Wang HC, Chang HT, Hsu YL, Chen YS, Chang CY. Systemic steroids in acute exacerbation of COPD ‐ from guidelines to bedside. Int J Clin Pharmacol Ther. 2011; 49: 705–8.
    1. Vollenweider DJ, Jarrett H, Steurer‐Stey CA, Garcia‐Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012; 12: CD010257.
    1. Fanning M, McKean M, Seymour K, Pillans P, Scott I. Adherence to guideline‐based antibiotic treatment for acute exacerbations of chronic obstructive pulmonary disease in an Australian tertiary hospital. Intern Med J. 2014; 44: 903–10.
    1. Beasley R, Chien J, Douglas J, Eastlake L, Farah C, King G, Moore R, Pilcher J, Richards M, Smith S et al. Thoracic Society of Australia and New Zealand oxygen guidelines for acute oxygen use in adults: ‘Swimming between the flags’. Respirology. 2015; 20: 1182–91.
    1. Edwards L, Perrin K, Williams M, Weatherall M, Beasley R. Randomised controlled crossover trial of the effect on PtCO2 of oxygen‐driven versus air‐driven nebulisers in severe chronic obstructive pulmonary disease. Emergency medicine journal : EMJ. 2012; 29: 894–8.
    1. Ram FS, Picot J, Lightowler J, Wedzicha JA. Non‐invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2004; 1: CD004104.
    1. Collaborative Research Group of Non‐invasive Mechanical Ventilation for Chronic Obstructive Pulmonary Disease . Early use of non‐invasive positive pressure ventilation for acute exacerbations of chronic obstructive pulmonary disease: a multicentre randomized controlled trial. Chin Med J (Engl). 2005; 118: 2034‐40.
    1. Verma AK, Mishra M, Kant S, Kumar A, Verma SK, Chaudhri S, Prabhuram J. Noninvasive mechanical ventilation: An 18‐month experience of two tertiary care hospitals in north India. Lung India. 2013; 30: 307–11.
    1. Lun CT, Chan VL, Leung WS, Cheung AP, Cheng SL, Tsui MS, Chu CM. A pilot randomized study comparing two methods of non‐invasive ventilation withdrawal after acute respiratory failure in chronic obstructive pulmonary disease. Respirology. 2013; 18: 814–9.
    1. Prasad SB, Chaudhry D, Khanna R. Role of noninvasive ventilation in weaning from mechanical ventilation in patients of chronic obstructive pulmonary disease: an Indian experience. Indian J Crit Care Med. 2009; 13: 207–12.
    1. Hu G, Zhou Y, Wu Y, Yu Y, Liang W, Ran P. The Pneumonia Severity Index as a Predictor of In‐Hospital Mortality in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. PLoS One. 2015; 10: e0133160.
    1. Ho TW, Tsai YJ, Ruan SY, Huang CT, Lai F, Yu CJ. In‐hospital and one‐year mortality and their predictors in patients hospitalized for first‐ever chronic obstructive pulmonary disease exacerbations: a nationwide population‐based study. PLoS One. 2014; 9: e114866.
    1. Kelly AM, Klim S. Is elevated troponin associated with in‐hospital mortality in emergency department patients admitted with chronic obstructive pulmonary disease? Eur J Emerg Med. 2013; 20: 54–7.
    1. Ai‐Ping C, Lee KH, Lim TK. In‐hospital and 5‐year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study. Chest. 2005; 128: 518–24.
    1. Soltani A, Reid D, Wills K, Walters EH. Prospective outcomes in patients with acute exacerbations of chronic obstructive pulmonary disease presenting to hospital: a generalisable clinical audit. Intern Med J. 2015; 45: 925–33.
    1. Fruchter O, Yigla M, Kramer MR. D‐dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation. Am J Med Sci. 2015; 349: 29–35.
    1. Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD, Hancox RJ. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011; 66: 764–8.
    1. Fruchter O, Yigla M. Cardiac troponin‐I predicts long‐term mortality in chronic obstructive pulmonary disease. Copd. 2009; 6: 155–61.
    1. Almagro P, Lopez Garcia F, Cabrera F, Montero L, Morchon D, Diez J, Soriano J. Comorbidity and gender‐related differences in patients hospitalized for COPD. The ECCO study. Respir Med. 2010; 104: 253–9.
    1. Chung LP, Winship P, Phung S, Lake F, Waterer G. Five‐year outcome in COPD patients after their first episode of acute exacerbation treated with non‐invasive ventilation. Respirology. 2010; 15: 1084–91.
    1. Pavasini R, d'Ascenzo F, Campo G, Biscaglia S, Ferri A, Contoli M, Papi A, Ceconi C, Ferrari R. Cardiac troponin elevation predicts all‐cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta‐analysis. Int J Cardiol. 2015; 191: 187–93.
    1. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 153: 967‐75.
    1. Nair S, Thomas E, Pearson SB, Henry MT. A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD. Chest 2005; 128: 48‐54.
    1. Bourbeau J, Nault D, Dang‐Tan T. Self‐management and behaviour modification in COPD. Patient Educ. Couns. 2004; 52: 271‐7.
    1. Zwerink M, Brusse‐Keizer M, van der Valk PD, Zielhuis GA, Monninkhof EM, van der Palen J, Frith PA, Effing T. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014; 3: CD002990.
    1. Casas A, Troosters T, Garcia‐Aymerich J, Roca J, Hernandez C, Alonso A, del Pozo F, de Toledo P, Anto JM, Rodriguez‐Roisin R, et al. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur. Respir. J. 2006; 28: 123‐30.
    1. Harrison SL, Janaudis‐Ferreira T, Brooks D, Desveaux L, Goldstein RS. Self‐management following an acute exacerbation of COPD: a systematic review. Chest 2015; 147: 646‐61.
    1. Puhan MA, Gimeno‐Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; 10: CD005305.
    1. Ko FW, Dai DL, Ngai J, Tung A, Ng S, Lai K, Fong R, Lau H, Tam W, Hui DS. Effect of early pulmonary rehabilitation on health care utilization and health status in patients hospitalized with acute exacerbations of COPD. Respirology 2011; 16: 617‐24.
    1. Harrison SL, Robertson N, Graham CD, Williams J, Steiner MC, Morgan MD, Singh SJ. Can we identify patients with different illness schema following an acute exacerbation of COPD: a cluster analysis. Respir. Med. 2014; 108: 319‐28.
    1. Maddocks M, Kon SS, Singh SJ, Man WD. Rehabilitation following hospitalization in patients with COPD: can it reduce readmissions? Respirology 2015; 20: 395‐404.
    1. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2006; 173: 1390‐413.
    1. Mesquita R, Vanfleteren LE, Franssen FM, Sarv J, Taib Z, Groenen MT, Gaffron S, Bruijnzeel PL, Pitta F, Wouters EF, et al. Objectively identified comorbidities in COPD: impact on pulmonary rehabilitation outcomes. Eur. Respir. J. 2015; 46: 545‐8.
    1. Gavish R, Levy A, Dekel OK, Karp E, Maimon N. The association between hospital readmission and pulmonologist follow‐up visits in patients with COPD. Chest 2015; 148: 375‐81.
    1. Sharma G, Kuo YF, Freeman JL, Zhang DD, Goodwin JS. Outpatient follow‐up visit and 30‐day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease. Arch. Intern. Med. 2010; 170: 1664‐70.
    1. Wong CX, Carson KV, Smith BJ. Home care by outreach nursing for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; 4: CD000994.
    1. Aiken LS, Butner J, Lockhart CA, Volk‐Craft BE, Hamilton G, Williams FG. Outcome evaluation of a randomized trial of the PhoenixCare intervention: program of case management and coordinated care for the seriously chronically ill. J. Palliat. Med. 2006; 9: 111‐26.
    1. Kwok T, Lum CM, Chan HS, Ma HM, Lee D, Woo J. A randomized, controlled trial of an intensive community nurse‐supported discharge program in preventing hospital readmissions of older patients with chronic lung disease. J. Am. Geriatr. Soc. 2004; 52: 1240‐6.
    1. Kruis AL, Smidt N, Assendelft WJ, Gussekloo J, Boland MR, Rutten‐van Molken M, Chavannes NH. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2013; 10: CD009437.
    1. Ko FW, Ngai JC, Ng SS, Chan KP, Cheung R, Leung MY, Pun MC, Hui DS. COPD care programme can reduce readmissions and in‐patient bed days. Respir. Med. 2014; 108: 1771‐8.
    1. Jeppesen E, Brurberg KG, Vist GE, Wedzicha JA, Wright JJ, Greenstone M, Walters JA. Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; 5: CD003573.
    1. Jakobsen AS, Laursen LC, Rydahl‐Hansen S, Ostergaard B, Gerds TA, Emme C, Schou L, Phanareth K. Home‐based telehealth hospitalization for exacerbation of chronic obstructive pulmonary disease: findings from “the virtual hospital” trial. Telemed. J. E. Health 2015; 21: 364‐73.
    1. Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P, Curren K, Balter MS, Bhutani M, Camp PG, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society guideline. Chest 2015; 147: 894‐942.
    1. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015; 385: 857‐66.
    1. Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Li X, Raiteri L, et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respir. Med. 2014; 2: 187‐94.
    1. Overington JD, Huang YC, Abramson MJ, Brown JL, Goddard JR, Bowman RV, Fong KM, Yang IA. Implementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions. J. Thorac. Dis. 2014; 6: 1586‐96.
    1. Suzuki T, Yanai M, Yamaya M, Satoh‐Nakagawa T, Sekizawa K, Ishida S, Sasaki H. Erythromycin and common cold in COPD. Chest 2001; 120: 730‐3.
    1. Banerjee D, Khair OA, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir. Med. 2005; 99: 208‐15.
    1. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 2008; 178: 1139‐47.
    1. Blasi F, Bonardi D, Aliberti S, Tarsia P, Confalonieri M, Amir O, Carone M, Di Marco F, Centanni S, Guffanti E. Long‐term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm. Pharmacol. Ther. 2010; 23: 200‐7.
    1. He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, Deng JM, MacNee W, Zhong XN. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 2010; 80: 445‐52.
    1. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr. , Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 365: 689‐98.
    1. Berkhof FF, Doornewaard‐ten Hertog NE, Uil SM, Kerstjens HA, van den Berg JW. Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respir. Res. 2013; 14: 125.
    1. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, Pelle AJ, Hoogsteden HC, Aerts JG, van der Eerden MM. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind, placebo‐controlled trial. Lancet Respir. Med. 2014; 2: 361‐8.
    1. Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst. Rev. 2013; 11: Cd009764.
    1. Ni W, Shao X, Cai X, Wei C, Cui J, Wang R, Liu Y. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta‐analysis. PLoS One 2015; 10: e0121257.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi